CHA ÀǰúÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ±èÇý¿Á
  • ¼Ò ¼Ó:
  • Àü¹®ºÐ¾ß : ³­ÀÓ ¹× ½ÃÇè°ü¾Æ±â ½Ã¼ú
  • Á÷ À§: ºñ°ø°³
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­:
  • ÆÑ ½º:
  • ÁÖ ¼Ò:
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

Àü¹®ºÐ¾ß

  • Àڱ󻸷Áõ, ³­°ü³­ÀÓ, ½À°ü¼º À¯»ê, ³­¼Ò±â´ÉÀúÇÏ, Àڱð格ö¼ú

Áø·áÀÏÁ¤

ÇÐÀ§ ¹× °æ·Â

[±³¼ö °æ·Â]
  • ¼º±Õ°ü´ëÇб³

  • °¡Å縯°üµ¿´ëÇб³

  • ´Ü±¹´ëÇб³

  • Â÷ÀǰúÇдëÇб³






  • [Áø·á °æ·Â]
  • ¼º±Õ°ü´ëÇб³ Á¦ÀϺ´¿ø »êºÎÀΰú

  • °¡Å縯°üµ¿´ëÇб³ Á¦ÀϺ´¿ø »êºÎÀΰú

  • ´Ü±¹´ëÇб³ Á¦ÀϺ´¿ø »êºÎÀΰú

  • Â÷ÀǰúÇдëÇб³ Â÷ ¿©¼ºÀÇÇבּ¸¼Ò ¼­¿ï¿ª Áø·áºÎ¿øÀå





  • [ÇÐȸ¡¤¿¬±¸¡¤¿¬¼ö¡¤¼ö»ó °æ·Â]
  • Northwestern University, Feinberg School of Medicine, Chicago

  • ´ëÇѰ¡Àӷº¸Á¸ÇÐȸ ÆíÁýÀÌ»ç

  • ´ëÇÑ»ý½ÄÀÇÇÐȸ ±³À°À§¿øÈ¸ À§¿ø

  • Clinical and Experimental Reproductive Medicine (CERM) ºÎÆíÁýÀÎ(2011-2018)

  • ´ëÇÑ»ý½ÄÀÇÇÐȸÁö ºÎÆíÁýÀÎ(2007-2010)



  • Á¦ 42ȸ Çѱ¹¸ðÀÚº¸°ÇÇÐȸ ÃÖ¿ì¼ö ³í¹®»ó (2017)

  • Á¦ 61ȸ ´ëÇÑ»ý½ÄÀÇÇÐȸ ¿ì¼ö ³í¹®»ó (2011)

  • Á¦ 60ȸ ´ëÇÑ»ý½ÄÀÇÇÐȸ ¿ì¼ö Æ÷½ºÅÍ»ó (2010)

  • [³í¹®]
  • Early gonadotropin-releasing hormone antagonist protocol in women with polycystic ovary syndrome: A preliminary randomized trial.Shin JJ, Park KE, Choi YM*, ±èÇý¿Á, Choi DH, Lee WS, Cho JH. Clin Exp Reprod Med. 2018 Sep;45(3):135-42.

  • The likelihood of achieving pregnancy through timed coitus in young infertile women with decreased ovarian reserve. Koo HS, ¼ÛÀοÁ, Â÷¼±È­, ¹ÚÂù¿ì, ±èÇý¿Á*. Clin Exp Reprod Med. 2018 Mar;45(1):31-7.

  • Predictors of live birth and pregnancy success after in vitro fertilization in infertile women aged 40 and over. ±èÇý¿Á, Sung N, ¼ÛÀοÁ*. Clin Exp Reprod Med. 2017 Jun;44(2):111-7.

  • Serum anti-Mullerian hormone levels decrease after endometriosis surgery. ±è¿µÁÖ, Â÷¼±È­, ±èÇý¿Á*. J Obstet Gynaecol. 2017 Apr;37(3):342-6.

  • ¹ÌÈ¥ ¿©¼ºÀÇ ÀӽŴɷ º¸Á¸À» À§ÇÑ ³­ÀÚ µ¿°á¿¡ ´ëÇÑ ÀνÄ. Á¶ÇѼ±, ±èÇý¿Á*. J Korean SocMatern Child Health. 2017 Jan;21(1):46-54.

  • Fertility of patients with polycystic ovary syndrome undergoing in vitro fertilization by age. ȲÀ¯ÀÓ, Â÷¼±È­, ¼ÛÀοÁ, ¾ç±¤¹®, ¹ÎÀÀ±â, ±èÇý¿Á*. Int J Gynaecol Obstet. 2016 Oct;135(1):91-5.

  • Reproductive outcomes of retransferring retained embryos in blastocyst transfer cycles. Yi HJ, ±¸È­¼±, Â÷¼±È­, ±èÇý¿Á, ¹ÚÂù¿ì, ¼ÛÀοÁ*. Clin Exp Reprod Med. 2016 Jun;43(2):133-8.

  • The Risk Factors and Pregnancy Outcomes of 48 Cases of Heterotopic Pregnancy from a Single Center. ÀüÁöÇö, ȲÀ¯ÀÓ, Shin IH, ¹ÚÂù¿ì, ¾ç±¤¹®, ±èÇý¿Á*. J Korean Med Sci. 2016 Jul;31(7):1094-9.

  • A high response to controlled ovarian stimulation induces premature luteinization with a negative impact on pregnancy outcomes in a gonadotropin-releasing hormone antagonist cycle. ±¸È­¼±, Â÷¼±È­, ±èÇý¿Á, ¼ÛÀοÁ, ¹ÎÀÀ±â, ¾ç±¤¹®, ¹ÚÂù¿ì*. Clin Exp Reprod Med. 2015 Dec;42(4):149-55.

  • Correlation between the Serum Luteinizing Hormone to Folliclestimulating Hormone Ratio and the Anti-Mullerian Hormone Levels in Normo-ovulatory Women. Lee JE, Yoon SH*, ±èÇý¿Á, ¹ÎÀÀ±â. J Korean Med Sci. 2015 Mar;30(3):296-300.

  • Complete phenotypic and metabolic profiles of a large consecutive cohort of untreated Korean women with polycystic ovary syndrome.Kim JJ, Hwang KR, Choi YM*, Moon SY, Chae SJ, ¹ÚÂù¿ì, ±èÇý¿Á, Choi DS, Kwon HC, Kang BM, Lee BS, Cho SH, Kim TJ, Kim T, Kim MJ, Park HY. Fertil Steril. 2014 May;101(5):1424-30.

  • Can high serum anti-Mullerian hormone levels predict the phenotypes of polycystic ovary syndrome (PCOS) and metabolic disturbances in PCOS patients? ȲÀ¯ÀÓ, ¼º³ª¿µ, ±¸È­¼±, Â÷¼±È­, ¹ÚÂù¿ì, ±èÁø¿µ, ¾ç±¤¹®, ¼ÛÀοÁ, ±Ã¹Ì°æ, °­Àμö, ±èÇý¿Á*. ClinExpReprod Med. 2013 Sep;40(3):135-40.

  • The effectiveness of earlier oocyte retrieval in the case of a premature luteinizing hormone surge on hCG day in in vitro fertilization-embryo transfer cycles.ÃÖ¹ÎÇý, Â÷¼±È­, ¹ÚÂù¿ì, ±èÁø¿µ, ¾ç±¤¹®, ¼ÛÀοÁ, ±Ã¹Ì°æ, °­Àμö, ±èÇý¿Á*. ClinExpReprod Med. 2013 Jun;40(2):90-4.

  • Comparison of assisted reproductive technology outcomes in infertile women with polycystic ovary syndrome: In vitro maturation, GnRH agonist, and GnRH antagonist cycles .ÃÖ¹ÎÇý, À̼±Èñ, ±èÇý¿Á, Â÷¼±È­, ±èÁø¿µ, ¾ç±¤¹®, ¼ÛÀοÁ, ±Ã¹Ì°æ, °­Àμö, ¹ÚÂù¿ì* ClinExpReprod Med. 2012 Dec;39(4):166-71. English.

  • ³­¼Ò Àڱ󻸷ÁõÀÇ ¼ö¼úÀû Ä¡·á¸¦ ¹ÞÀº ¿©¼ºÀÇ Ç÷Áß Ç׹흰ü È£¸£¸ó ¿¬±¸.ÀÌÀç¶ó, À̹οµ, ¹ÚÇý¿ø, Â÷¼±È­, ¹ÚÂù¿ì, ±èÁø¿µ, ¾ç±¤¹®, ¼ÛÀοÁ, ±Ã¹Ì°æ, °­Àμö, ±èÇý¿Á* Korean J Obstet Gynecol. 2012 Dec;55(12):935-9. Korean.

  • Serum anti-Mullerian hormone is a better predictor of ovarian response than FSH and age in IVF patients with endometriosis.À¯ÁöÈñ, Â÷¼±È­, ¹ÚÂù¿ì, ±èÁø¿µ, ¾ç±¤¹®, ¼ÛÀοÁ, ±Ã¹Ì°æ, °­Àμö, ±èÇý¿Á*. ClinExpReprod Med. 2011 Dec;38(4):222-7.

  • Laparoscopic management of early primary peritoneal pregnancy: a case report .±¸È­¼±, ¹èÁÖ¿¬, °­Àμö, ±Ã¹Ì°æ, ±èÇý¿Á, Â÷¼±È­, ÃÖ¹ÎÇý, ±èÁö¿µ, ¾ç±¤¹®*. Clin Exp Reprod Med. 2011 Jun;38(2):109-14.

  • ÁßÁõ Àڱ󻸷ÁõÀÇ ¼ö¼úÀû Ä¡·á ÈÄ Ã¼¿Ü¼öÁ¤ÀÇ °á°ú.¾ç½ÂÇå, ±èÇý¿Á*, ¼º³ª¿µ, ¾ÈÇö¼÷, Ãß¿¬½Ç, ¾ç±¤¹®, ¼ÛÀοÁ, ±Ã¹Ì°æ, °­Àμö. Korean J Obstet Gynecol. 2011 Sep;54(9):517-22.

  • Serum anti-Mullerian hormone levels as a predictor of the ovarian response and IVF outcomes.ÃÖ¹ÎÇý, À¯ÁöÈñ, ±èÇý¿Á*, Â÷¼±È­, ¹ÚÂù¿ì, ¾ç±¤¹®, ¼ÛÀοÁ, ±Ã¹Ì°æ, °­Àμö. ClinExpReprod Med. 2011 Sep;38(3):153-8.

  • Comparison of mild ovarian stimulation with conventional ovarian stimulation in poor responders.À¯ÁöÈñ, Â÷¼±È­, ¹ÚÂù¿ì, ±èÁø¿µ, ¾ç±¤¹®, ¼ÛÀοÁ, ±Ã¹Ì°æ, °­Àμö, ±èÇý¿Á*. Clin Exp Reprod Med. 2011 Sep;38(3):159-63.

  • Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for in vitro fertilization: A comparative study. Ãß¿¬½Ç, ÇѾֶó, ¾ç½ÂÇå, ¼º³ª¿µ, Â÷¼±È­, ±èÇý¿Á, ¹ÚÂù¿ì, ¼ÛÀοÁ, ±Ã¹Ì°æ, °­Àμö, ¾ç±¤¹®*. Korean J Obstet Gynecol. 2011 Oct;54(10):599-604. English

  • Adverse pregnancy outcomes with assisted reproductive technology in non-obese women with polycystic ovary syndrome: a case-control study.ÇѾֶó, ±èÇý¿Á*, Â÷¼±È­, ¹ÚÂù¿ì, ±èÁø¿µ, ¾ç±¤¹®, ¼ÛÀοÁ, ±Ã¹Ì°æ, °­Àμö. Clin Exp Reprod Med. 2011 Jun;38(2):103-8.

  • Age specific serum anti-Mullerian hormone levels in 1,298 Korean women with regular menstruation.À¯ÁöÈñ, ±èÇý¿Á*, Â÷¼±È­, ¹ÚÂù¿ì, ¾ç±¤¹®, ¼ÛÀοÁ, ±Ã¹Ì°æ, °­Àμö. Clin Exp Reprod Med. 2011 Jun;38(2):93-7.

  • Non-invasive prenatal detection of achondroplasia using circulating fetal DNA in maternal plasma.ÀÓÁöÇý, ±è¹ÌÁø, ±è½Å¿µ, ±èÇý¿Á, ¼Û¹ÌÁø, ±è¹ÎÇü, ¹Ú¼Ò¿¬, ¾çÀçÇõ, ·ùÇö¹Ì*. Assist Reprod Genet. 2011 Feb;28(2):167-72.

  • Prediction and prevention of ovarian hyperstimulation syndrome. ±èÇý¿Á, °­Àμö*. ´ëÇÑ»ý½ÄÀÇÇÐȸÁö. 2010 Dec;37(4):293-305. Korean.

  • ³­°ü Æó¼â¿¡ ±âÀÎÇÑ ºÒÀÓ È¯ÀÚ¿¡¼­ ³­°ü °³Åë¼úÀÇ È¿¿ë¼º.¹ÚÂù¿ì, Â÷¼±È­, ¾ç±¤¹®, ÇѾֶó, À¯ÁöÈñ, ¼ÛÀοÁ, ±èÇý¿Á, °­Àμö, ±Ã¹Ì°æ, À̰æ»ó*. ´ëÇÑ»ý½ÄÀÇÇÐȸÁö. 2010 Dec;37(4):321-7.

  • ¸»ÃÊÇ÷¾× ÀÚ¿¬»ìÇØ¼¼Æ÷ ºÐȹ ¹× ¼¼Æ÷¿ëÇØ Ȱ¼ºµµ ºÐ¼®À» ÅëÇÑ ½À°ü¼º À¯»ê À§Ç豺ÀÇ Áø´ÜÀû À¯¿ë¼º¿¡ °üÇÑ ¿¬±¸.ÃÖÁö¿µ, Ȳ¼öÁø, ÇѾֶó, À¯ÁöÈñ, ¹Úµ¿¿í, ¹ÚÂù¿ì, ±èÇý¿Á, Â÷¼±È­, ±èÁø¿µ, ¼ÛÀοÁ, ±Ã¹Ì°æ, °­Àμö, ¾ç±¤¹®*. ´ëÇÑ»ý½ÄÀÇÇÐȸÁö. 2010 Jun;37(2):115-24.

  • Àú¼º¼±ÀÚ±ØÈ£¸£¸ó¼º¼±ÀúÇÏÁõ ¿©¼º¿¡¼­ º¸Á¶»ý½Ä¼úÀÇÀÓ½ÅÀ².ÇѾֶó, ¹ÚÂù¿ì*, Â÷¼±È­, ±èÇý¿Á, ¾ç±¤¹®, ±èÁø¿µ, ±Ã¹Ì°æ, °­Àμö, ¼ÛÀοÁ. ´ëÇÑ»ý½ÄÀÇÇÐȸÁö. 2010 Mar;37(1):49-56.

  • ¹«Á¤ÀÚÁõÀ» º¸ÀÌ´Â ³²¼º°ú Á¤»ó »ý½Ä·ÂÀ» °¡Áø ¿©¼ºÀÇ °¡°è¿¡¼­ °üÂûµÈ X ¿°»öüÀÇ Pericentric Inversion. À̺½ÀÌ, ·ùÇö¹Ì, À̹®Èñ, ¹ÚÁÖ¿¬, ±èÁø¿ì, ÀÌÁß½Ä, ±èÇý¿Á, ±è¹ÎÇü, ¹Ú¼Ò¿¬* ´ëÇÑÀÇÇÐÀ¯ÀüÇÐȸÁö. 2008 Dec;5(2):139-44

  • ºñÆó¼â¼º ¹«Á¤ÀÚÁõ ȯÀÚ¿¡¼­ÀÇ °íȯÀÇ Á¶Á÷º´¸®ÇÐÀû Áø´Ü¿¡ µû¸¥ ü¿Ü¼öÁ¤½Ã¼ú °á°úÀÇ ºñ±³¹ÚÂù¿ì, ¼­ÁÖÅÂ*, ¹Ú¿ë¼®, ±èÇý¿Á, ¾ç±¤¹®, ±èÁø¿µ, ±Ã¹Ì°æ, °­Àμö, ¼ÛÀοÁ ´ëÇÑ»ý½ÄÀÇÇÐȸÁö. 2008 Dec;35(4):293-301

  • °ú¹è¶õÀ¯µµ ½Ã Ç÷Áß AMH¿Í ³­¼Ò ¹ÝÀÀ¼º°úÀÇ »ó°ü°ü°è:¿¹ÃøÀÎÀڷμ­ÀÇ È¿¿ë¼º¾È¿µ¼±, ±èÁø¿µ*, Á¶¿¬Áø, ±è¹ÎÁö, ±èÇý¿Á, ¹ÚÂù¿ì, ¼ÛÀοÁ, ±Ã¹Ì°æ, °­Àμö ´ëÇÑ»ý½ÄÀÇÇÐȸÁö. 2008 Dec;35(4):309-17

  • Àú¹ÝÀÀ±ºÀÇ Ã¼¿Ü¼öÁ¤¿¡¼­ ÇÑ °³ÀÇ ¹è¾ÆÀÌ½Ä ½Ã Àӽſ¡ ¿µÇâÀ» ÁÖ´Â ¿äÀÎ ±èÇý¿Á, ±è¹ÎÁö, ¿¬¸íÁø, Â÷¼±È­, ±Ã¹Ì°æ, ¼ÛÀοÁ* ´ëÇÑ»ý½ÄÀÇÇÐȸÁö. 2008 Sep;35(3):213-221

  • ³­¼ÒÀÇ ±â´ÉÀÌ ÀúÇÏµÈ ºÒÀÓ È¯ÀÚ¿¡¼­ ¿¬·É ¹× ±âÀú Ç÷Áß FSH ¼öÄ¡°¡ ü¿Ü¼öÁ¤½Ã¼úÀÇ ¿¹ÈÄ¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ °üÇÑ ¿¬±¸À¯¿µ, ±è¹ÎÁö, Á¶¿¬Áø, ¿¬¸íÁø, ¾È¿µ¼±, Â÷¼±È­, ±èÇý¿Á, ¹ÚÂù¿ì, ±èÁø¿µ, ¼ÛÀοÁ, ±Ã¹Ì°æ, °­Àμö, ÀüÁ¾¿µ, ¾ç±¤¹®* ´ëÇÑ»ý½ÄÀÇÇÐȸÁö. 2007 Sep;34(3):189-96

  • Outcomes of Controlled Ovarian Hyperstimulation/In Vitro fertilization for Infertile Patients with Borderline Ovarian Tumor after Conservative Treatment.¹ÚÂù¿ì, ¾ç±¤¹®*, ±èÇý¿Á, È«¼º¶õ, ±èÅÂÁø, ÀÓ°æÅÃ, À̱âÇå, °­Àμö J Korean Med Sci. 2007 Sep;22(Suppl):S134-S138

  • Àú¹ÝÀÀ±ºÀÇ Ã¼¿Ü¼öÁ¤À» À§ÇÑ °ú¹è¶õÀ¯µµ¿¡ ÀÖ¾î GnRH Antagonist ¿ä¹ý°ú GnRH Agonist Flare Up ¿ä¹ýÀÇ È¿¿ë¼º¿¡ °üÇÑ ¿¬±¸¾È¿µ¼±, ¿¬¸íÁø, Á¶¿¬Áø, ±è¹ÎÁö, °­Àμö, ±Ã¹Ì°æ, ±èÁø¿µ, ¾ç±¤¹®, ¹ÚÂù¿ì, ±èÇý¿Á, Â÷¼±È­, ¼ÛÀοÁ* ´ëÇÑ»ý½ÄÀÇÇÐȸÁö. 2007 Jun;34(2):125-131

  • Expression of CD44s, vascular endothelial growth factor, matrix metalloproteinase-2 and Ki-67 in peritoneal, rectovaginal and ovarian endometriosis ±èÇý¿Á, ¾ç±¤¹®, °­Àμö, ±Ã¹Ì°æ, Kim HS, Zhang X, ±èÀμ±* J Reprod Med. 2007 Mar;52(3):207-13

  • ü¿Ü¼öÁ¤½Ã¼ú½Ã °æÁõÀÇ Àڱ󻸷Áõ°ú ¿øÀκҸíÀÇ ºÒÀÓ ¿©¼ºÀÇ ºñ±³ ±èÇý¿Á, ¹ÚÂù¿ì, ¼ÛÀοÁ, ±Ã¹Ì°æ* ´ëÇÑ»êºÎÀΰúÇÐȸÀâÁö. 2007 Feb;50(2):322-328

  • Àڱ󻸷ÁõÀÌ ÀÖ´Â ºÒÀÓ ¿©¼º¿¡¼­ Áߵ¿¡ µû¸¥ ü¿Ü¼öÁ¤ÀÇ °á°ú ºñ±³ ±èÇý¿Á, °­Àμö* ´ëÇѺÒÀÓÇÐȸÁö. 2006 Dec;33(4):219-227

  • ü¿Ü¼öÁ¤À¸·Î ÀÓ½ÅµÈ ½Öžƿ¡¼­ ¼öÁ¤¹æ¹ý¿¡ µû¸¥ ÀӽŠÁß±â triple testÀÇ ÀÇÀÇ ±èÇý¿Á, ¼ÛÀοÁ*, Â÷¼±È­, ÇÑÁ¤·Ä, ½ÅÁß½Ä, °­Àμö, ±Ã¹Ì°æ ´ëÇÑ»êºÎÀΰúÇÐȸÁö. 2006 Nov;49(11):2341-2346

  • 37¼¼ ÀÌ»óÀÇ È¯ÀÚ¿¡¼­ ü¿Ü¼öÁ¤ ½Ã¼ú½Ã GnRH Agonist ÁÖ±â¿Í GnRH Antagonist ÁÖ±âÀÇ ºñ±³ ¿¬±¸.¹ÚÂù¿ì, Â÷¼±È­, ±èÇØ¼÷, ±èÇý¿Á, ¾ç±¤¹®, ±èÁø¿µ, ¼ÛÀοÁ, À¯±ÙÀç, °­Àμö, ±Ã¹Ì°æ* ´ëÇѺÒÀÓÇÐȸÁö. 2005 Sep;32(3):261-8.

  • °è·ùÀ¯»ê ȯÀÚ¿¡¼­ Àڱà °æÀ» ÅëÇÑ À¯»ê¾Æ °üÂûÀÇ Áø´ÜÀû À¯¿ë¼º¿¡ °üÇÑ ¿¬±¸ ¾ç±¤¹®, Â÷¼±È­, ±èÈñ¼÷, ±èÁø¿µ, ±èÇý¿Á, ¾ÈÇö°æ, ÃÖÁؽÄ, ·ùÇö¹Ì, °­Àμö, ±Ã¹Ì°æ* ´ëÇÑ»êºÎÀΰúÇÐȸÀâÁö. 2005 Feb;48(2):363-9.

  • ½À°ü¼º À¯»ê ȯÀÚ¿¡¼­ Àú¿ë·® ¸é¿ª±Û·ÎºÒ¸° Ä¡·á¿Í ¸»ÃÊÇ÷¾× ³» Natural Killer (NK) ¼¼Æ÷ÀÇ ÀÓ°èÄ¡¿¡ °üÇÑ ¿¬±¸ Â÷¼±È­, ±èÇØ¼÷, ±èÇý¿Á, ¼ÛÀοÁ, À¯±ÙÀç, ±Ã¹Ì°æ, °­Àμö, ¾ç±¤¹®* ´ëÇѺÒÀÓÇÐȸÁö. 2005 Sep;32(3):217-22.

  • Ŭ·Î¹ÌÆæ¿¡ ºÎÀûÀýÇÑ ¹ÝÀÀÀ» º¸ÀÌ´Â ´Ù³¶¼º ³­¼Ò ÁõÈıº ȯÀÚ¿¡¼­ Aromatase InhibitorÀÇ À¯¿ë¼º ±èÇý¿Á*, ¾ç±¤¹®, Çã°É, ¹ÚÂù¿ì, Â÷¼±È­, ±èÇØ¼÷, ±èÁø¿µ, ¼ÛÀοÁ, ±Ã¹Ì°æ´ëÇѺÒÀÓÇÐȸÁö. 2005 Mar;32(1):27-32.

  • º¸Á¶»ý½Ä¼ú¿¡¼­Àú¿ë·® Aspirin°ú Prednisolone º´ÇÕÅõ¿©ÀÇ È¿¿ë¼º Çã°É, ¹ÚÂù¿ì, ±èÇý¿Á, ±èÁø¿µ, ¾ç±¤¹®, ±Ã¹Ì°æ*, °­Àμö ´ëÇÑ»êºÎÀΰúÇÐȸÁö. 2003 Sep;46(9):1665-1673

  • HPV 16 ¾ç¼º ÀڱðæºÎ¾Ï¼¼Æ÷ÁÖ¿¡¼­Cdna Microarray¿¡ ÀÇÇÑ À¯ÀüÀÚ ¹ßÇö Çã°É, ÀÓÁ¤È­, ÀåÇâ¶õ, ¹ÚÂù¿ì, ±èÇý¿Á, Á¶ÁØÇü, °­Àμö, ±è¿µ½Ä, ±èÀμ±* ´ëÇÑ»êºÎÀΰúÇÐȸÁö. 2003 Apr;46(4):810-819

  • µ¿°áº¸Á¸ ¹è¾ÆÀ̽Ŀ¡¼­ ºÐºñ±â Àڱ󻸷 À¯µµ½ÃÇÁ·Î°Ô½ºÅ×·Ð Åõ¿© ¹æ¹ý¿¡ µû¸¥ Âø»óÀ²°ú ÀÓ½ÅÀ²ÀÇ ºñ±³ ¹ÚÂù¿ì, Çã°É, ±è¹®¿µ, ¼ÛÇöÁ¤, ±èÇý¿Á, ¾ç±¤¹®, ±èÁø¿µ, ¼ÛÀοÁ, À¯±ÙÀç, õ±¤¿ì, º¯Çý°æ, ±Ã¹Ì°æ, °­Àμö* ´ëÇѺÒÀÓÇÐȸÁö. 2003 Sep;30(3):193-202

  • ³­°ü ºÒÀÓȯÀÚ¿¡¼­ ³­°ü °³Åë¼ú½Ã Áø´Üº¹°­°æÀÇ È¿¿ë¼º ¹ÚÂù¿ì, ±èÇý¿Á, Çã°É, ¾ç±¤¹®, ±èÁø¿µ, ¼ÛÀοÁ, À¯±ÙÀç, ÀüÁ¾¿µ, À̰æ»ó, °­Àμö, ±Ã¹Ì°æ* ´ëÇѺÒÀÓÇÐȸÁö. 2003 Jun;30(2):141-150

  • ´ÙÅÂÀӽۨ¼ö¼ú(Multifetal Pregnancy Reduction)ÈÄ ¿ÏÀüžƼսǿ¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÀÎÀÚ ±èÇý¿Á, ±è¹®¿µ, ¼ÛÇöÁ¤, ¹ÚÂù¿ì, Çã°É, ±èÁø¿µ, ¾ç±¤¹®, À¯±ÙÀç, ¼ÛÀοÁ, ÀüÁ¾¿µ, ±Ã¹Ì°æ, °­Àμö* ´ëÇѺÒÀÓÇÐȸÁö. 2003 Mar;30(1):39-45

  • Copyright ¨Ï chamc, All rights reserved.

    ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

    • °­³²Â÷º´¿ø
    • ºÐ´çÂ÷º´¿ø
    • ºÐ´çÂ÷¿©¼ºº´¿ø
    • ±¸¹ÌÂ÷º´¿ø
    • ¿©¼ºÀÇÇבּ¸¼Ò
    • Â÷¿ò

    ÀüÈ­¹®ÀÇ

    • °­³²Â÷º´¿ø 02.3468.3000
    • ºÐ´çÂ÷º´¿ø 031.780.5000
    • Â÷¿ò 02.3015.5300
    • ±¸¹ÌÂ÷º´¿ø 054.450.9700
    • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
    • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
    • ºÐ´çÁ¾Çհǰ­ÁõÁø¼¾ÅÍ 031.780.5940
    • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
    • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
    • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729